Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Guselkumab for Hidradenitis Suppurativa, a Mode of Action Study. The HiGUS-trial

NCT04061395 is registered in ClinicalTrials.gov with University Medical Center Groningen as lead sponsor.

NCT NCT04061395
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04061395 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Guselkumab for Hidradenitis Suppurativa, a Mode of Action Study. The HiGUS-trial
Lead sponsor
University Medical Center Groningen
Phase
Phase 2
Overall status
Completed
Start date
October 1, 2019
Completion date
April 1, 2022
Enrollment
20 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

hidradenitis suppurativa